Download PDF
Drug Res (Stuttg) 2015; 65(12): 650-657
DOI: 10.1055/s-0034-1398687
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

A Meta-analysis of Sequential Intravenous/Oral Moxifloxacin Monotherapy for Treatment of Skin and Skin Structure Infections

Y. Chu
1   Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, China
2   College of Pharmaceutical Science, China Medical University, Shenyang, China
,
J. Qu
3   Department of Pharmacy, Dalian Medical University, Dalian, China
,
L.-Y. Qu
1   Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, China
2   College of Pharmaceutical Science, China Medical University, Shenyang, China
,
Y.-F. Luo
1   Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, China
2   College of Pharmaceutical Science, China Medical University, Shenyang, China
,
M.-Y. Jiang
1   Department of Pharmacy, The First Affiliated Hospital of China Medical University, Shenyang, China
2   College of Pharmaceutical Science, China Medical University, Shenyang, China
› Author Affiliations
Further Information

Publication History

received 14 August 2014

accepted 22 January 2015

Publication Date:
12 June 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Moxifloxacin is widely recognized for the treatment of bacterial infections of the respiratory tract such as community acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis. However, the use of moxifloxacin for skin infections is much valued in recent years. This study is to compare the clinical efficacy and safety of moxifloxacin monotherapy among adults with skin and skin structure infections. The meta-analysis of RCTs is conducted by searching Medline, Embase, Pubmed and the Cochrane Library. 6 RCTs, involving a total of 2 608 patients, were included in the meta-analysis. English and Chinese language papers were reviewed. The results of the meta-analysis showed that the moxifloxacin monotherapy has similar clinical cure rate, bacteriological success rates and mortality compared with the control group. The drug-related adverse of moxifloxacin was significantly higher than that in the control group, although the overall incidence of adverse events, serious adverse events, and serious drug-related adverse events were similar between the compared treatment groups. Through this meta-analysis, we can draw a conclusion that moxifloxacin monotherapy has similar effectiveness and relative safety as other recommended antibiotics for the treatment of SSSIs. At the same time, it possesses the superior bacteria eradication rate. The once-daily dosing of moxifloxacin monotherapy may be a useful alternative for other recommended antibiotic therapy.

Key words

moxifloxacin - skin infections - randomized controlled - meta-analysis
 

  • References

  • 1 Ball P, Stahlmann R, Kublin R et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and post marketing studies. Clin Ther 2004; 26: 940-950
    CrossrefPubMedGoogle Scholar
  • 2 Lipsky BA, Giordano P, Choudhari S et al. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin – tazobactam/amoxicillin – clavulanate. Journal of Antimicrobial Chemotherapy 2007; 60: 370-376
    CrossrefPubMedGoogle Scholar
  • 3 Ben-Quan WU, Pradhan YC, Zhang T-T et al. Comparing therapeutic and adverse effects of moxifloxacin and levofloxacin in treatment of community acquired pneumonia: A meta-analysis of randomized controlled trials. African Journal of Microbiology Research 2012; 6: 1893-1901
    PubMedGoogle Scholar
  • 4 Cao Y-C, Chen X-P, Zu-Sen XU. A Randomized, Double-Blind, Compared Study of Moxifloxacin for Treatment of Skin Infection. Chin J Derm Venereol 2002; 16: 379-381
    PubMedGoogle Scholar
  • 5 Culley CM, Lacy MK, Klutman N et al. Moxifloxacin: Clinical efficacy and safety. Am J Health-Syst Pharm 2001; 58: 379-388
    PubMedGoogle Scholar
  • 6 Chen F, Zheng N, Wang Y et al. Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomized controlled trials. Int J Clin Pract 2013; 67: 834-842
    CrossrefPubMedGoogle Scholar
  • 7 Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 2003; 63: 1459-1480
    CrossrefPubMedGoogle Scholar
  • 8 Higgins J, Thompson S, Deeks J et al. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serve Res Policy 2002; 7: 51-61
    PubMedGoogle Scholar
  • 9 Gyssens IC, Dryden M, Kujath P et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobac tam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother 2011; 66: 2632-2642
    CrossrefPubMedGoogle Scholar
  • 10 Bogner JR, Kutaiman A, Esguerra-Alcalen M. Moxifloxacin in Complicated Skin and Skin Structure Infections (cSSSIs): A Prospective, International, Non-interventional, Observational Study. Adv Ther 2013; 30: 630-643
    CrossrefPubMedGoogle Scholar
  • 11 Parish LC, Routh HB, Miskin B et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000; 54: 497-503
    PubMedGoogle Scholar
  • 12 Lipsky BA, Weigelt JA, Gupta V et al. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. J Antimicrob Chemother 2007; 60: 370-376
    CrossrefPubMedGoogle Scholar
  • 13 Mao Mao AN, Zui ZOU, Hui S et al. Moxifloxacin monotherapy versus β-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomized controlled trials. International Journal of Antimicrobial Agents 2010; 36: 58-65
    CrossrefPubMedGoogle Scholar
  • 14 Dinubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. Journal of Antimicrobial Chemotherapy 2004; 53: 37-50
    PubMedGoogle Scholar
  • 15 Tulkens P, Arvis P, Kruesmann F. Moxifloxacin Safety: An Analysis of 14 Years of Clinical Data. Drugs R D 2012; 12: 71-100
    CrossrefPubMedGoogle Scholar
  • 16 Giordano P, Song J, Pertel P et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. International Journal of Antimicrobial Agents 2005; 26: 357-365
    CrossrefPubMedGoogle Scholar
  • 17 Nichols RL. Optimal treatment of complicated skin and skin structure infections. Journal of Antimicrobial Chemotherapy 1999; 44: 19-23
    PubMedGoogle Scholar
  • 18 Moher D, Liberati A, Tetzlaff J et al. the PRISMA Group . Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. Ann Intern Med 2009; 151: 264-269
    CrossrefPubMedGoogle Scholar
  • 19 Raghavan M, Linden PK. Newer treatment options for skin and soft tissue infections. Drugs 2004; 64: 1621-1642
    CrossrefPubMedGoogle Scholar
  • 20 Song JX, Wassell JT. Sample size for K 2×2 tables in equivalence studies using Cochran’s statistic. Control Clin Trials 2003; 24: 378-389
    CrossrefPubMedGoogle Scholar
  • 21 Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43: 83-90
    PubMedGoogle Scholar
  • 22 Stass H, Kubitza D. Profile of moxifloxacin drug interactions. Clin Infect Dis 2001; 32: 47-50
    PubMedGoogle Scholar
  • 23 Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-1055
    CrossrefPubMedGoogle Scholar
  • 24 Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351-1355
    CrossrefPubMedGoogle Scholar
  • 25 Wang A-P, Yu J, Wu Y et al. A Randomized Double-blind Control Clinical Study on moxifloxacin for treatment of Bacterial Skin Infections. Chin J C!in Pharmacol 2003; 19: 243-247
    PubMedGoogle Scholar
  • 26 Wise R, Andrews JM, Marshall G et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999; 43: 1508-1510
    PubMedGoogle Scholar
  • 27 Yuan XIN, Liang B-B, Wang RUI et al. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials. Journal of Chemotherapy 2012; 24: 257-267
    CrossrefPubMedGoogle Scholar
  • 28 Mu YP, Liu RL, Wang LQ et al. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomized controlled trials. Int J Clin Pract 2012; 66: 210-217
    CrossrefPubMedGoogle Scholar